Today: 9 June 2026
Browse Category

NASDAQ:LEGN 8 December 2025 - 3 June 2026

Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
3 June 2026
···
Legend Biotech (LEGN) stock slips in premarket after 9% surge as Gilead-Arcellx deal spotlights Carvykti rivals

Legend Biotech (LEGN) stock slips in premarket after 9% surge as Gilead-Arcellx deal spotlights Carvykti rivals

Legend Biotech shares slipped 0.2% to $19.72 in premarket trading Tuesday after a 9% jump the previous session, following news of Gilead’s $7.8 billion deal to buy Arcellx. The acquisition put focus on rival CAR-T therapies, with Arcellx’s anito-cel under FDA review and analysts citing possible safety advantages over Legend’s Carvykti, which generated $1.9 billion in 2025 sales.
24 February 2026
·
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech stock hits a fresh 52-week low as biotech lags — JPMorgan update looms

Legend Biotech shares dropped 4.7% to $20.49 Monday, hitting a 52-week low and leaving the stock down 55% from its high. The decline comes ahead of the J.P. Morgan Healthcare Conference, where CEO Ying Huang is set to present Jan. 14. Broader biotech stocks also fell, with key ETFs down about 1%. Investors are watching for updates on CARVYKTI, Legend’s CAR-T therapy for multiple myeloma.
5 January 2026
·
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Legend Biotech fell 12.8% to a new 52-week low Monday, leading U.S. stock declines as the S&P 500 hovered just below record highs ahead of the Fed’s rate decision. Marvell Technology dropped 8.6%, Unilever ADR lost 7%, and several others slid 4–6%. Traders priced in an 85–90% chance of a 25-basis-point Fed rate cut this week.
8 December 2025
············

Stock Market Today

  • U.S. Markets Rise on Chipmakers Rally Amid Iran-Israel Ceasefire Signals
    June 8, 2026, 6:40 PM EDT. U.S. stock indexes closed mixed on Monday, with the S&P 500 up 0.30% and the Nasdaq 100 gaining 1.58%, led by a rally in chipmakers and AI infrastructure stocks amid renewed enthusiasm for artificial intelligence. Dow Jones edged down 0.16%, weighed by a decline in Apple shares following lukewarm reactions to its AI platform update. WTI crude oil prices fell after Iran indicated the end of its current military operation against Israel, easing geopolitical tensions and supporting market recovery. Treasury yields rose, with 10-year note yields hitting a two-week high at 4.58%, pressured by strong U.S. payroll data and elevated Treasury supply ahead of auctions. Markets price a 3% chance of a 25 basis point Federal Reserve rate hike in mid-June. Overseas, Asian and European stocks declined amid global risk-off sentiment.

Latest articles

T1 Energy Shares Dip After KORE Power Files New Update

T1 Energy Shares Dip After KORE Power Files New Update

9 June 2026
T1 Energy shares slid 3.2% to $9.13 after a new SEC filing revealed up to $24.7 million in stock-linked payments for its $32 million KORE Power acquisition, spotlighting dilution risks as the company expands into battery storage and data-center power; the deal’s structure and timing come as T1 seeks growth funding and investors weigh near-term costs against future EBITDA targets.
OpenAI IPO filing puts AI rally at center stage for Wall Street

OpenAI IPO filing puts AI rally at center stage for Wall Street

9 June 2026
OpenAI has confidentially filed for a possible IPO, but investors won’t see key financials—including revenue quality, cash burn, and compute costs—until the S-1 goes public; with $2 billion monthly revenue and a recent $852 billion valuation, the filing signals a pivotal shift as AI giants race for public capital amid rising infrastructure costs and growing competition from Anthropic.
Wall Street Volatility Index Jumps as Chip Stocks Swing

Wall Street Volatility Index Jumps as Chip Stocks Swing

9 June 2026
The VIX plunged 12% to 18.92 as chip stocks rebounded sharply, with the Philadelphia Semiconductor Index jumping 5.6% and Intel soaring 11.2% after a major Google order, clawing back part of Friday’s $1.3 trillion rout; investors remain cautious ahead of key inflation data, interest rate decisions, and Middle East risks.
UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
Go toTop